Drug Trial Radar · NCT00268203
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
765
Actual
Start
Sep 1998
Primary completion
Mar 2000
Study completion Feb 2013
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This is a single arm, multi-center, expanded access study of Iodine I 131 Tositumomab (BEXXAR) therapeutic regimen for patients with relapsed or refractory low-grade or transformed low-grade non-Hodgkin's B-cell lymphoma. The primary objective is to make Iodine I 131 Tositumomab more broadly available to patients. Secondary endpoints will be to obtain additional safety and efficacy information for this treatment regimen. Post study drug administration follow-ups will continue for up to ten years. These will include blood-work and adverse event assessments for 13 weeks post dosing, patient response evaluations at Week 13, Months 6, 12, 18, 24, and Long-Term Follow-ups every 6 months until the elapse of 5 years from the dosimetric dose and then annually thereafter through year 10. Thyroid function will be monitored annually during Long-term follow-up.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
Iodine I 131 Tositumomab Therapeutic RegimenBiological
Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete ResponseTime frame: From randomization until the first documented complete response or partial response (up to 161 months)
- Number of Participants With Confirmed Response (Complete Response or Partial Response) and Confirmed Complete ResponseTime frame: From randomization until the first documented complete response or partial response (up to 161 months)
- Duration of Response for Participants With Unconfirmed Response (CR+PR)Time frame: From the time of the first documented response (CR or PR) until disease progression (up to 161 months)
- Duration of Response for Participants With Confirmed Response (CR+PR)Time frame: From the time of the first documented response (CR or PR) until disease progression (up to 161 months)
- Duration of Response (DOR) in Unconfirmed Complete RespondersTime frame: From the time of the first documented unconfirmed CR until PD (up to 161 months)
- Duration of Response (DOR) in Confirmed Complete RespondersTime frame: From the time of the first documented CR until PD (up to 161 months)
- Time to Progression or DeathTime frame: From the treatment start date to the first documented incidence of disease progression (PD) or death (up to 161 months)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.